Physician profile
Michael John Lim Solon
NPI 1295478337
$9,733.84
in general payments reported to CMS, 2019-2025
20 companies · $4,524 in 2025
The $4,524 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,282 · 2024: $3,928 · 2025: $4,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,722 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,721.69 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,477.66 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,458.95 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $1,392.63 | 2023-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $1,138.59 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $949.87 | 2023-2025 | Caplyta |
| Abbvie INC. | $942.01 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $552.15 | 2024-2025 | Cobenfy |
| Corium, LLC | $437.37 | 2023-2025 | Azstarys |
| Axsome Therapeutics, INC. | $227.08 | 2024-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $225.43 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $156.34 | 2024 | Fanapt |
| Ironshore Pharmaceuticals INC. | $131.55 | 2023-2024 | Jornay Pm |
| Neurocrine Biosciences, INC. | $126.47 | 2023-2025 | Ingrezza |
| Melinta Therapeutics, LLC | $125.01 | 2025 | Rezzayo |
| Lilly USA, LLC | $125.00 | 2025 | Kisunla |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $100.90 | 2023-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $64.91 | 2023-2024 | Invega Sustenna |
| Tris Pharma INC | $41.15 | 2025 | Onyda Xr, Dyanavel Xr |
| Lundbeck LLC | $40.69 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $20.08 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael John Solon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.